Phathom Pharmaceuticals, Inc.
PHAT
$10.58
-$0.21-1.95%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 175.11M | 147.19M | 114.04M | 81.86M | 55.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 175.11M | 147.19M | 114.04M | 81.86M | 55.25M |
| Cost of Revenue | 22.60M | 18.77M | 14.93M | 11.27M | 7.97M |
| Gross Profit | 152.51M | 128.42M | 99.11M | 70.59M | 47.28M |
| SG&A Expenses | 279.72M | 308.03M | 332.57M | 323.13M | 290.66M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 335.10M | 360.67M | 383.04M | 368.24M | 332.72M |
| Operating Income | -159.99M | -213.48M | -269.00M | -286.38M | -277.47M |
| Income Before Tax | -221.25M | -274.55M | -330.15M | -345.79M | -334.33M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -221.25 | -274.55 | -330.15 | -345.79 | -334.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -221.25M | -274.55M | -330.15M | -345.79M | -334.33M |
| EBIT | -159.99M | -213.48M | -269.00M | -286.38M | -277.47M |
| EBITDA | -159.35M | -212.78M | -268.27M | -285.62M | -276.67M |
| EPS Basic | -3.05 | -3.81 | -4.73 | -5.24 | -5.35 |
| Normalized Basic EPS | -1.91 | -2.38 | -2.96 | -3.28 | -3.35 |
| EPS Diluted | -3.05 | -3.81 | -4.73 | -5.24 | -5.35 |
| Normalized Diluted EPS | -1.91 | -2.38 | -2.96 | -3.28 | -3.35 |
| Average Basic Shares Outstanding | 291.65M | 288.88M | 280.11M | 266.20M | 252.60M |
| Average Diluted Shares Outstanding | 291.65M | 288.88M | 280.11M | 266.20M | 252.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |